These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 10526702)
1. Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States. Cohen M; Ferguson JJ; Harrington RA Clin Cardiol; 1999 Oct; 22 Suppl 6(Suppl 6):VI2-12. PubMed ID: 10526702 [TBL] [Abstract][Full Text] [Related]
2. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
3. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
4. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Harrington RA Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233 [TBL] [Abstract][Full Text] [Related]
5. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
6. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
8. Managing acute coronary syndrome: evidence-based approaches. Spinler SA Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441 [TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Truong KM; Amankwa K; Kucukarslan S Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855 [TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Heeschen C; Hamm CW; Moliterno DJ; Califf RM; White HD; Kleiman NS; Théroux P; Topol EJ Circulation; 2001 Dec; 104(23):2767-71. PubMed ID: 11733392 [TBL] [Abstract][Full Text] [Related]
11. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
12. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Campbell KR; Ohman EM; Cantor W; Lincoff AM Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178 [TBL] [Abstract][Full Text] [Related]
13. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
14. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260 [TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986 [TBL] [Abstract][Full Text] [Related]